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Position statements have been issued by the International
Menopause Society (IMS)1 and the South African Menopause
Society (SAMS)2 in response to publication of the Heart and
Estrogen/Progestin Replacement Study (HERS),3 the Estrogen
Replacement and Atherosclerosis (ERA) study,4 the Women’s
Health Initiative (WHI) oestrogen-plus-progestin arm,5-7 the
Million Women Study (MWS)8 and the oestrogen arm of the
WHI.
9
These papers caused major concern among women, dismay
among medical and nursing experts and opinion leaders and
confusion among general practitioners.
The trials and response of inter alia the American Food and
Drug Administration (FDA) and the European Medicine
Evaluation Agency were evaluated against observational
studies, meta-analysis and pre-clinical research by the IMS.
Randomised controlled trials (RCTs) are the gold standard,
but their results must not be generalised to populations they
were not designed to study.  By design the WHI5 limited the
intake of vasomotor symptomatic women in the early years of
the menopause to less than 10%.  This highlights a major
difference between RCTs and observations trials.  Symptomatic
women seek help and choose observational trials, while
asymptomatic women are willing to participate in RCTs.
The menopause transition, namely the first 5 or maximum 10
years of the menopause, may well be the ‘window of
opportunity’ for cardiovascular disease and dementia
protection using hormone replacement therapy (HRT).
The HERS3 and ERA4 studies are secondary prevention trials.
Over 40% of the cohort of the two WHI trials5,9 were at high
risk of cardiovascular disease and two-thirds were over the age
of 60 years.
In the WHI trial5 the ratio of disease outcome for coronary
heart disease, venous thromboembolism (VTE), stroke and
breast cancer shows impressive increases from year 4 to 5, and
even larger reductions from year 5 to 6 and later.  The
significance of this unsustained rise in year 5 is uncertain.  The
changes correlate more closely with the placebo outcome
inversely than with treatment incidence.  The year 6 and later
drop is discounted by the writers: ‘the narrowing of the
difference by year 5 is because HR [hazard ratio] estimates tend
to be unstable beyond 6 years after randomization’.  No
references are given.  The planned duration of the trials was 8.5
years.  Over 25% of subjects had used HRT before the start of
the trial! The oestrogen arm9 was stopped in the 7th year
because of lack of cardiovascular protection and increased
stroke risk.
The HR of venous thromboembolic disease in the WHI trial
is over 2.005 and is the only clinical outcome not to show a
weak association (HR between 1.00 and 2.00) and to have a
statistically significant nominal 95% confidence interval (CI).
The data for the risks of HRT and breast cancer are
inconsistent.
In a recent review in the Journal of Internal Medicine (2004; 19:
791-804 of 30 clinical studies involving 25 000 women, Salpeter
found that women under the age of 60 years on HRT had a
39% lower death rate than non-users and that in the over-60
age group the death rate was similar in users and non-users.
The media, both medical and lay, should be careful about
publishing comments on trials until they have been peer
reviewed, otherwise incorrect conclusions will be published, as
with the WHI on a trial that was outdated when published as it
applied to treatment schedules from 1992.  By 2002 HRT was
no longer prescribed for women of all ages, only to those in the
early years of the transition, which according to WHI data may
be beneficial for cardiovascular and Alzheimer’s disease.
HRT and menopausal disease
HRT is acknowledged as the best treatment for two conditions,
namely vasomotor symptoms and atrophic vaginitis.  For other
conditions it is preventive or possibly preventive.
Vasomotor symptoms
Vasomotor symptoms may cause sleep disorders and
secondary depression.
Atrophic vaginitis
Atrophic vaginitis causes symptoms of vaginal dryness and
dyspareunia.  The oestrogen receptor only responds to
systemic oestrogens in 70% of women and local oestrogen
therapy may be preferred or necessary.  Unopposed local
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oestrogen may cause endometrial hyperplasia and yearly
ultrasound, endometrial biopsy or progesterone challenge
should be performed.
Osteoporosis
Osteoporosis prevention and hip and lumbar vertebral fracture
reduction are the commonest indications for HRT.
Colorectal cancer
Most trials, including the WHI5 but not the oestrogen arm of
the WHI,9 found that HRT reduces incidence of colorectal
cancer.
Cardiovascular disease
Both the IMS and SAMS disagree with the National Institute of
Health (NIH) that the oestrogen-plus-progestin arm of the
WHI5 is a primary prevention trial.
The menopause transition, namely the first 5 or maximum 10
years of the menopause without atherosclerosis and
hypertension may well be the ‘window of opportunity’ for
cardiovascular protection using HRT.  This has been suggested
by surrogate markers, animal studies,10 observational trials11
and at least 4 meta-analyses.
Evaluation of cardiovascular events in the Women’s Hope
Study and the Menopause Study Group
12
using varying doses
of conjugated equine oestrogen and medroxyprogesterone
acetate in healthy, early menopausal women (average age 53
and 54 years) showed no increased risk of cardiovascular
events in the first year of use, unlike the WHI5 and HERS.3
Both the HERS3 and the ERA study4 are secondary
prevention trials.  Although claiming to be a primary
prevention trial, the WHI5 limited the intake of symptomatic
women in the early years of the menopause to less than 10%.13
A power analysis of the WHI showed that it was 10-fold
underpowered to detect an early oestrogen cardioprotective
effect13 of the magnitude reported in observational studies such
as the Nurses Health Study.11
In the WHI trials the relative risk (RR) for coronary heart
disease was 0.9 for the first 10 years since commencement of
the menopause6 but 1.29 in the entire trial overall,5 and 0.56 for
women aged 50 - 59 years and 0.91 overall.9 The RR for starting
HRT early in the menopause is similar to that in many
observational trials including a meta-analysis14 based on
observational studies up to mid-1997 (RR 0.70, 95% CI: 0.65 -
0.75) for oestrogen-only users, and 0.66 (95% CI: 0.53 - 0.84) for
7 studies reporting on cyclical oestrogen-plus-progestin use.
The WHI5,9 and HERS3 show no increased risk with duration of
use.
SAMS suggests that cardiovascular disease has not been
sufficiently studied in RCTs to allow any firm conclusion, while
the IMS states that HRT appears to provide protection against
potential heart disease if started early in the menopause.
Stroke
According to SAMS primary prevention of stroke has not been
sufficiently studied in RCTs to allow a firm conclusion.
The two WHI trials5,9,15 and HERS3 involve older women.  The
Women’s Estrogen Trial for stroke (WEST),16 a secondary
prevention trial on 71-year-old women, showed an increased
rate of fatal stroke and an unsustained increase in overall
stroke rate in the first 6 months.
The WHI paper15 states that prior studies have given
conflicting results in relation to stroke risk, 4 showing
decreased risk, 3 no effect and 3, including a recent meta-
analysis, increased risk.  Analysis of women who started
oestrogen only between the ages of 50 and 59 years have only
0.1 extra cases of stroke per 10 000 women.9
Dementia
Dementia risk was increased in the 65-year-old group in the
WHIMS studies.17,18 In the Cache County Study,19 where women
were a mean age of 73.2 years, HRT users had a reduced risk of
Alzheimer’s disease (HR 0.59, 95% CI: 0.36 - 0.96).  Only long-
term current users (more than 10 years) appeared to benefit
(HR 0.41, 95% CI: 0.17 - 0.86), probably representing women
starting HRT in the early menopausal years.  These results are
consistent with those of 2 other prospective studies.20,21
Breast cancer
The data on HRT and breast cancer are inconsistent and pre-
2000 results are best summed up in the conclusions of Bush et
al.22 and the Collaborative Group.23 ‘The evidence did not
support the hypotheses that estrogen use increases the risk of
breast cancer and that combined hormone therapy increases
the risk more than estrogen only.  Additional observational
studies are unlikely to alter this conclusion.  Although a small
increase in breast cancer risk with hormone therapy or an
increased risk with long duration of use (15 years or more)
cannot be ruled out, the likehood of this must be small,’22 and
‘little information was available about long duration of use of
any specific preparation’.23 The post-2000 results are similarly
inconsistent (Table I).
The modest increased risk of invasive breast cancer after 5
years of HRT use in some studies is, as suggested by SAMS,
probably promotion of a pre-existing subclinical cancer not the
initiation of a malignant mutation.29
SAMS quotes no increase in carcinoma in situ as a reason for
the promotion theory and this is supported by a statistical
analysis of breast cancer risk for duration of use and the
following 10 years.  Breast cancer takes 7 - 10 years to grow to a
clinically or radiologically detectable size.30 The 5-year
increased risk is 2 - 5 years less than would be expected if HRT
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initiated breast cancer.  The risk disappears 5 years after
stopping HRT23 and is followed by a further slight reduction
over the next 5 years.23,25,27
All types of HRT in the MWS8 induced an increased breast
cancer risk starting from the first year of use, suggesting that
breast cancer was present at the start of therapy and was not
induced by hormones.
The review by Bush et al.22 consistently noted a reduced risk
of death from breast cancer in hormone users compared with
non-users.  The WHI7 reported that tumour size was slightly
greater and lymph node metastases more frequent in hormone
users than non-users.7 This must be assessed against the
knowledge that 19.7% were past and 6.4% current HRT users at
baseline and that the HR dropped from 1.26 to 1.06 if baseline
current users were excluded.7 Baseline users were not excluded
from the statistics in the report by Chlebowski et al.7
Venous thromboembolism (VTE)
The risk using conjugated equine oestrogen 0.625 mg and
medroxyprogesterone acetate 2.5 mg in older women in the
HERS3 and WHI5 trials was nearly doubled, but with the
oestrogen-only arm9 it was only 1.33 (95% CI: 0.99 - 1.77).  The
risk reduced with duration of use.  Oestrogen plus progestin
increased the risks associated with age, overweight, and factor
V Leiden in the WHI31 and showed only 1 extra VTE per 10 000
women in the 50 - 59-year age group.9
Full haematological screening will establish who is at high
risk of the disease.  At a presentation in Cape Town L Speroff
(2004) agreed that a previous challenge using the combined
oral contraceptive for a reasonable duration of time (more than
2 years) would probably exclude the majority of women at
high risk.
Age of commencement of HRT
Both societies agree that premature ovarian failure requires
HRT until the average age of the menopause, namely 51 years.
The WHI confirmed the impression suggested by the HERS3
and the ERA study4 in which Herrington et al. state that
‘another possible explanation for our results are that estrogen is
more effective in preventing atheroselerosis than in slowing the
progression once it is established’.  HRT should be started in
the first 5 or maximum 10 years of the menopause.
Indications for HRT
SAMS state that HRT should only be initiated for specific
proven indications, as discussed above, provided there are no
contraindications.  These include vasomotor symptoms and/or
associated sleep disorders of early menopause. Systemic and
local HT is effective in the prevention and treatment of vulval
and vaginal atrophy, decreasing the incidence of vertebral and
hip fracture and EPT for reducing the risk of colorectal cancer.’
The statement ‘HT (HRT) is effective in preventing the bone
loss associated with early menopause’ requires explanation.
Does ‘early menopause’ mean only in association with
premature ovarian failure or only in the early transition?  The
WHI has shown a preventive effect at all ages.  
‘The effect of HT on primary prevention of CHD and stroke
has not been sufficiently studied in RCTs to allow any firm
conclusion’ and ‘HT is not indicated for the prevention or
treatment of Alzheimer’s disease’.2
The IMS guideline agrees with the SAMS indications for
HRT use but differs in its review with regard to heart and brain
disease: ‘initiation of HRT during the menopausal transition
appears to provide protection against complication of the
climacteric such as fracture and potentially heart disease and
brain disease’.
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Table I. Relative risk of HRT and breast cancer — post-2000 trials and studies  
Oestrogen replacement therapy Oestrogen-plus-progestin therapy Any HRT
Women’s Health
Initiative (WHI)9 0.77 - -
Million Women’s
Study8 1.30 2.00 -
Ross et al.24 1.06 1.38 (sequential) 1.10
1.09 (continuous combined)
Schairer et al.25 1.1 1.3 -
Weiss et al.26 0.84 0.96 (sequential) -
1.35 (continuous combined)
Moorman et al.27 0.8 - 0.8
Heart and Estrogen/
Progestin Replacement
Study (HERS)3 - 1.27 (continuous combined) -
WHI5 - 1.26 (including previous users)
1.06 (excluding previous users)
De Ligneres et al.28 - - 0.98
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Duration of use
The IMS and SAMS are in total disagreement on duration of
HRT use.
According to the IMS guidelines ‘There are no new reasons
to place mandatory limitations on the length of treatment,
including arbitrary cessation of HRT in women who started
replacement during the menopausal transition and remain
symptom-free while on hormones.  Judging from the
accelerated rate of cardiovascular events after premature
menopause and the loss of cardioprotection after stopping
HRT, such cessation may even be harmful.’
According to the SAMS statement, ‘The need for
continuation of HT should be re-evaluated annually.  The need
for continuing treatment of menopausal symptoms can be
determined by temporarily discontinuing therapy after about 
4 - 5 years.  As a general rule, the risks involved with EPT for
the first 5 years after menopause and with ET for the first 10
years after menopause are very small.  Treatment for periods
exceeding these limits or the age of 60 years must be
invidualised in terms of risk and benefit.  The decision is best
left in the hands of the menopausal expert and the informed
patient.’ This statement is difficult to understand – as SAMS
are unable to suggest guidelines, who are the menopause
experts in South Africa?
The statistics of the WHI and HERS show little change in risk
with duration of use other than reduction in total death5,9 and
coronary heart disease death.32,33 The risk increases with
duration of HRT use only in stroke patients.9
The effect of duration of HRT use and breast cancer can be
assessed from Table II.  Although inconsistent it would suggest
promotion of a pre-existing breast cancer and not initiation of a
new cancer.
HRT dose
The lowest effective dose should be the objective. Early in the
menopause and with premature ovarian failure higher doses
may be required, but these can be reduced slowly.
Route of administration
Non-oral oestrogens lack first-pass effect on the liver and are
recommended in women with liver disease, raised triglyceride
levels (at baseline or after oral oestrogen use), increased risk of
venous thrombosis and high risk of breast cancer especially in
the presence of excessive breast sulphatase activity.34
Women with high cholesterol, low high-density lipoprotein
(HDL) and normal triglyceride levels will benefit more from
oral oestrogens.  Oral oestrogens increase sex hormone-binding
globulin (SHBG) via hepatic stimulation and the same amount
of free oestradiol is available from 2 mg 17-β−οestradiol and a
50 µg oestradiol patch.
Types of HRT, tibolone and raloxifene
In the clinical guidelines section, SAMS states that ‘These
statements are currently applicable to all estrogens and
progestins as well as tibolone’. The IMS disagrees – ‘The
different types and regimens of HRT do not necessarily have
the same tissue and metabolic effects and should not be
grouped together as having a class effect.’
Only one paper, the MWS,8 has suggested that tibolone
(Livifem) increases the risk of breast cancer.  This is thought to
be due to preferential prescribing for high-risk breast cancer
patients, as biologically it has been called a selective oestrogen
enzyme modulator and should reduce the risk of breast cancer.
HDL is reduced by tibolone but according to David Cook this
may not increase the risk of cardiovascular disease. An
example is Tangiers disease. RCTs are ongoing and are
necessary for this product.
Interestingly, SAMS has not mentioned raloxifene (Evista)
which increases the risk of VTE, flushing and cramps but 
reduces breast cancer risk within 40 months.35 This suggests
inhibition of existing breast cancer.  What is the prognosis
when raloxifene is stopped? How long can raloxifene be used
for?
Table II. Effect of duration of HRT use (plus 5 years) on breast cancer*
Increased risk Risk unchanged Reduced risk Risk −1 (less than placebo)
Oestrogen replacement 2 (8) (25) 1 (25) 1 (24) 3 (9) (26) (27)
Oestrogen progestin 4 (8) (24) (25) (26) 1 (25) 1 (33) 1 (27)
Any HRT 2 (24) (28) 1 (27) 0 0
* Number of published papers. The numbers in brackets refer to the references in this article.
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Conclusions
Both the IMS and SAMS recommend HRT for premature
ovarian failure, vasomotor symptoms, atrophic vulval and
vaginal pathology (often local oestrogen with regular check-
ups with regard to endometrial safety), and prevention of
osteoporosis and hip and vertebral fractures, and advise
starting HRT in the first 5 or 10 years of the menopause.  HRT
reduces the risk of colorectal cancer but this reduction was not
shown in the oestrogen arm of the WHI trial.9 The dosage
should be the lowest that is effective.
SAMS feels that no firm conclusion can be made on the
primary prevention of cardiovascular disease or stroke using
HRT and that HRT is not indicated for the prevention and
treatment of dementia.
The IMS quotes many studies and trials to suggest the
opposing view and states that during the menopausal
transition HRT provides protection against complications such
as heart and brain disease.  HRT promotes breast cancer
minimally and possibly more with opposed than unopposed
oestrogens.29 HRT users have reduced mortality and improved
survival rates.22 A 5-year moratorium is not justified on
statistical grounds as only breast cancer possibly increases with
duration of use and this is due to promotion of an existing
breast cancer with improved prognosis.  For possible
cardiovascular and dementia prevention and reduced risk of
VTE, starting age should be early in the menopause.
Hopefully this paper will give our health care providers an
unbiased view.  Over the past 7 years recommendations have
swung from use for all, to no use at all, to use of low dose early
in the menopause to protect against conditions of old age.
More trials are required to establish disease outcome and
contraindications to treatment.
I personally use the IMS guidelines as reasons are given for
duration of use and prevention of cardiovascular disease and
dementia.  Explanation of both recommendations will help
women make un unbiased decision.
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